专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2017218891A1 SITE-SPECIFIC CROSSLINKING OF ANTIBODIES 审中-公开
标题翻译：抗体的位点特异性交联
公开(公告)号：WO2017218891A1
公开(公告)日：2017-12-21
申请号：PCT/US2017/037871
申请日：2017-06-16
申请人： LIFE TECHNOLOGIES CORPORATION
发明人： AGNEW, Brian , AGGELER, Robert , BRAWER, Rolando
IPC分类号： C07K16/46 , C12P21/00 , C12P21/06 , A61K47/54
CPC分类号： C07K16/468 , A61K9/0021 , A61K47/60 , A61K47/6879 , A61K47/6881 , A61K47/6913 , C07K2317/10 , C07K2317/31 , C07K2317/41 , C07K2317/52 , C07K2317/54 , C07K2317/622 , C07K2319/30 , C12N9/2402 , C12N15/113 , C12N2310/14 , C12N2310/3513 , C12P21/005 , C12Y302/01018 , C12Y302/01023 , C12Y302/01096 , G01N33/6854
摘要： Methods are provided for making bispecific antibodies and antibody conjugates comprising site-specifically cross-linking two or more antibodies, antibody fragments or Fc-fusion proteins. Also provided are compositions and uses for the bispecific antibodies and antibody conjugates. The bispecific antibodies may be used to treat a disease or condition. Also provided are methods for site-specifically conjugating a liposome, an mRNA or an siRNA to an antibody, and uses of the antibody-conjugated liposome, mRNA or siRNA.
摘要翻译：提供了制备包含位点特异性交联两种或更多种抗体，抗体片段或Fc-融合蛋白的双特异性抗体和抗体缀合物的方法。还提供了双特异性抗体和抗体缀合物的组合物和用途。双特异性抗体可用于治疗疾病或病症。还提供了用于将脂质体，mRNA或siRNA与抗体位点特异性缀合的方法，以及抗体缀合的脂质体，mRNA或siRNA的用途。

2. 发明申请

WO2016164480A1 ANTIGEN BINDING COMPLEX HAVING AGONISTIC ACTIVITY AND METHODS OF USE 审中-公开
标题翻译：具有激活活性的抗原结合复合物及其使用方法
公开(公告)号：WO2016164480A1
公开(公告)日：2016-10-13
申请号：PCT/US2016/026245
申请日：2016-04-06
申请人： GENENTECH, INC. , F. HOFFMANN-LA ROCHE AG
发明人： LAZAR, Greg , KIM, Jeong , ZHU, Jing , YANG, Yanli , BREZSKI, Randall
IPC分类号： C07K16/28 , A61K39/00 , C07K16/32
CPC分类号： C07K16/2875 , A61K38/02 , A61K39/395 , A61K47/6881 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K16/2863 , C07K16/2878 , C07K16/32 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/524 , C07K2317/526 , C07K2317/622 , C07K2317/71 , C07K2317/73 , C07K2317/75 , C07K2317/92
摘要： Provided herein are antigen binding polypeptides and complexes thereof having agonist activity. Also provided are methods for screening for complexes or polypeptides having agonist activity, enhancing the agonist activity of a polypeptide, and for agonizing a cell surface receptor using the complexes and polypeptide described herein.
摘要翻译：本文提供具有激动剂活性的抗原结合多肽及其复合物。还提供了筛选具有激动剂活性的复合物或多肽，增强多肽的激动剂活性以及使用本文所述的复合物和多肽刺激细胞表面受体的方法。

3. 发明申请

WO2015187969A3 ANTIBODY GUIDED VACCINES AND METHODS OF USE FOR GENERATION OF RAPID MATURE IMMUNE RESPONSES 审中-公开
标题翻译：抗体指导疫苗和使用快速成熟免疫应答的方法
公开(公告)号：WO2015187969A3
公开(公告)日：2016-01-21
申请号：PCT/US2015034229
申请日：2015-06-04
申请人： UNIV ARKANSAS , TEXAS A & M UNIV SYS
发明人： BERGHMAN LUC , CHEN CHANG-HSIN , CHOU WEN-KO , VUONG CHRISTINE , WAGHELA SURYAKANT , MWANGI WAITHAKA , HARGIS BILLY , ABI-GHANEM DAAD , BIELKE LISA
IPC分类号： A61K39/395
CPC分类号： A61K39/39 , A61K9/0019 , A61K9/0048 , A61K9/0056 , A61K9/08 , A61K9/10 , A61K39/145 , A61K47/36 , A61K47/6881 , A61K2039/505 , A61K2039/5252 , A61K2039/54 , A61K2039/542 , A61K2039/543 , A61K2039/552 , A61K2039/55516 , A61K2039/575 , A61K2039/6056 , A61K2039/6087 , A61K2039/625 , C07K16/1018 , C07K16/1282 , C07K16/2878 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/622 , C07K2317/75 , C07K2317/76 , G01N33/6878
摘要： Adjuvant compositions, vaccines, constructs for preparing the adjuvant compositions and vaccines and methods of using the adjuvant compositions and vaccines to enhance immune responses in subjects are provided herein. In particular, a rapid antibody response to the vaccine including both IgG (in the circulation) and slgA (mucosal secretory IgA) is elicited. The adjuvants and vaccines may be used for sub-cutaneous or mucosal administration enabling low cost, effective vaccination of subjects. A method of epitope mapping to rapidly identify antigenic epitopes is also provided.
摘要翻译：本文提供佐剂组合物，疫苗，用于制备佐剂组合物和疫苗的构建体以及使用佐剂组合物和疫苗以增强受试者的免疫应答的方法。特别地，引起对疫苗的快速抗体应答，包括IgG（循环中）和slgA（粘膜分泌型IgA）。佐剂和疫苗可以用于皮下或粘膜给药，从而能够低成本，有效地接种受试者。还提供了用于快速鉴定抗原表位的表位作图的方法。

4. 发明申请

WO01038318A1 CYTOTOXIC AGENTS COMPRISING TAXANES AND THEIR THERAPEUTIC USE 审中-公开
标题翻译：包含TAXANES及其治疗用途的细胞毒素
公开(公告)号：WO01038318A1
公开(公告)日：2001-05-31
申请号：PCT/US2000/030149
申请日：2000-11-21
IPC分类号： C07D305/08 , A61K31/337 , A61K31/452 , A61K31/496 , A61K31/5377 , A61K47/48 , A61P35/00 , A61P43/00 , C07D305/14 , C07D413/02 , C07K16/28 , C07K16/32 , A61K39/395 , C07K16/30
CPC分类号： C07D305/14 , A61K31/337 , A61K47/6803 , A61K47/6849 , A61K47/6851 , A61K47/6881 , A61K2039/505 , C07K16/2863 , C07K16/32 , Y02A50/423 , Y02A50/491
摘要： A cytotoxic agent comprising one or more taxanes linked to a cell binding agent. A therapeutic composition for killing selected cell populations comprising: (A) a cytotoxic amount of one or more taxanes covalently bonded to a cell binding agent through a linking group, and (B) a pharmaceutically acceptable carrier, diluent or excipient. A method for killing selected cell populations comprising contacting target cells or tissue containing target cells with an effective amount of a cytotoxic agent comprising one or more taxanes linked to a cell binding agent. Novel sulfur-containing taxanes.
摘要翻译：包含与细胞结合剂连接的一种或多种紫杉烷类的细胞毒性剂。一种用于杀死所选细胞群的治疗组合物，其包含：（A）细胞毒性量的一种或多种通过连接基团与细胞结合剂共价结合的紫杉烷，和（B）药学上可接受的载体，稀释剂或赋形剂。一种杀死所选细胞群体的方法，包括使含有目标细胞的靶细胞或组织与有效量的细胞毒性剂接触，所述细胞毒剂包含与细胞结合剂连接的一种或多种紫杉烷类。新型含硫紫杉烷。

5. 发明申请

WO1992005801A1 PRIMATE ERYTHROCYTE BOUND MONOCLONAL ANTIBODY HETEROPOLYMERS 审中-公开
公开(公告)号：WO1992005801A1
公开(公告)日：1992-04-16
申请号：PCT/US1991007158
申请日：1991-10-04
申请人： UNIVERSITY OF VIRGINIA PATENTS FOUNDATION , TAYLOR, Ronald, P. , SUTHERLAND, William, M. , REIST, Craig , WRIGHT, Eleanor, L. , WEBB, Donna , LABUGUEN, Ronald
发明人： UNIVERSITY OF VIRGINIA PATENTS FOUNDATION
IPC分类号： A61K39/395
CPC分类号： A61K35/18 , A61K38/00 , A61K47/6849 , A61K47/6881 , A61K47/6901 , C07K16/28
摘要： The application relates to the use of antibodies in therapy. Monoclonal antibody heteropolymers are described which comprise a monoclonal antibody specific for the CR1 receptor on primate red blood cells covalently linked to a second monoclonal antibody specific for an antigen to be cleared from the circulatory system. The monoclonal antibody heteropolymers may be injected directly into a patient's circulatory system. Alternatively, red blood cells removed from a patient or a suitable donor may be contacted with the monoclonal antibody heteropolymers and then administered to the patient.
摘要翻译：本申请涉及抗体在治疗中的应用。描述了单克隆抗体杂聚物，其包含与针对要从循环系统中清除的抗原特异性的第二单克隆抗体共价连接的灵长类红细胞上CR1受体特异性的单克隆抗体。单克隆抗体杂聚物可以直接注射到患者的循环系统中。或者，从患者或合适的供体中取出的红细胞可以与单克隆抗体杂聚物接触，然后给予患者。

6. 发明申请

WO2017143171A1 NUCLEIC ACID CARRIERS AND THERAPEUTIC METHODS OF USE 审中-公开
标题翻译：核酸载体和治疗方法的使用
公开(公告)号：WO2017143171A1
公开(公告)日：2017-08-24
申请号：PCT/US2017/018343
申请日：2017-02-17
申请人： GENISPHERE LLC
发明人： GETTS, Robert, C. , KADUSHIN, James, M. , GETTS, Lori
IPC分类号： A61K47/48 , A61K49/00 , A61K49/12 , C08G83/00
CPC分类号： A61K47/6881 , A61K47/6803 , A61K47/6811 , A61K47/6849 , A61K47/6889 , C08G83/00
摘要： The present disclosure provides nucleic acid carriers comprising one or more layers comprising multiple monomers, wherein each monomer comprises: a first and a second oligonucleotide; wherein a central portion of each of the first and second oligonucleotides is complementary to each other, forming a double-stranded region, wherein the two terminal portions of the first oligonucleotide are not complementary to the two terminal portions of the second oligonucleotide, forming four terminal arms; and at least one targeting agent conjugated to at least one peripheral terminal arm, wherein when the at least one targeting agent is an miRNA. The present disclosure also provides pharmaceutical composition comprising any of the nucleic acid carriers described herein, and a pharmaceutically acceptable vehicle. The present disclosure also provides methods of inducing an immune response in an animal comprising administering to the animal any of the nucleic acid carriers described herein.
摘要翻译：本公开提供了包含一个或多个包含多个单体的层的核酸载体，其中每个单体包含：第一和第二寡核苷酸; 其中第一和第二寡核苷酸各自的中心部分互相互补，形成双链区，其中第一寡核苷酸的两个末端部分不与第二寡核苷酸的两个末端部分互补，形成四个末端武器; 和至少一种缀合于至少一个外围末端臂的靶向剂，其中当所述至少一种靶向剂是miRNA时。本公开内容还提供了包含本文所述的任何核酸载体和药学上可接受的载体的药物组合物。本公开内容还提供了在动物中诱导免疫应答的方法，包括向动物施用本文所述的任何核酸载体。

7. 发明申请

WO2016126611A4 TARGETING MOIETY PEPTIDE EPITOPE COMPLEXES HAVING A PLURALITY OF T-CELL EPITOPES 审中-公开
标题翻译：靶向具有多个T细胞表位的多肽肽表位复合物
公开(公告)号：WO2016126611A4
公开(公告)日：2016-09-15
申请号：PCT/US2016015983
申请日：2016-02-01
申请人： THE UNIV OF BIRMINGHAM , COBBOLD MARK , MILLAR DAVID
发明人： COBBOLD MARK , MILLAR DAVID
IPC分类号： A61K47/48 , A61P35/00 , A61P35/02 , A61P37/00
CPC分类号： A61K39/245 , A61K47/646 , A61K47/6811 , A61K47/6849 , A61K47/6881 , A61K2039/585 , A61K2039/6056 , C12N2710/16134
摘要： A variety of targeting moiety peptide epitope complexes (TPECs) are described in different embodiments. In each of the embodiments, however, a targeting moiety may be used to deliver the TPEC to an area of unwanted cells, allowing for a therapeutic effect to be delivered locally. The TPEC also contains a plurality of T-cell epitopes. The TPEC further comprises cleavage sites that release the T-cell epitopes from the targeting agent, and in some embodiments from each other, when they are in the microenvironment of the unwanted cells. Although the arrangement and number of T-cell epitopes varies in different embodiments described herein, once cleaved from the targeting agent (and any neighboring T-cell epitopes), the T-cell epitopes function by stimulating an immune response against the unwanted cells.
摘要翻译：在不同的实施方案中描述了多种靶向部分肽表位复合物（TPEC）。然而，在每个实施方案中，靶向部分可用于将TPEC递送至不需要的细胞区域，从而允许局部递送治疗效果。 TPEC还含有多种T细胞表位。当TPEC处于不需要的细胞的微环境中时，TPEC还包含从靶向试剂释放T细胞表位并且在一些实施方式中彼此释放的切割位点。尽管T细胞表位的排列和数量在本文所述的不同实施方式中变化，但是一旦从靶向剂（和任何相邻的T细胞表位）切下，T细胞表位通过刺激针对不需要的细胞的免疫应答而起作用。

8. 发明申请

WO2012065044A3 TREATING BLADDER TUMOR CELLS USING FIBRONECTIN ATTACHMENT PROTEIN AS A TARGET 审中-公开
标题翻译：使用纤维蛋白连接蛋白作为目标治疗刀片肿瘤细胞
公开(公告)号：WO2012065044A3
公开(公告)日：2014-04-03
申请号：PCT/US2011060339
申请日：2011-11-11
申请人： PURDUE RESEARCH FOUNDATION , AGUILAR RUBEN CLAUDIO , RATLIFF TIMOTHY , THOMPSON DAVID , CRIST SCOTT
发明人： AGUILAR RUBEN CLAUDIO , RATLIFF TIMOTHY , THOMPSON DAVID , CRIST SCOTT
IPC分类号： A61K39/00 , C07K16/00
CPC分类号： A61K47/48246 , A61K38/164 , A61K47/48507 , A61K47/48823 , A61K47/64 , A61K47/6835 , A61K47/6881 , A61K47/6913 , A61K47/6927 , A61K2039/505 , C07K16/12 , C07K16/1278 , C07K16/28 , C07K16/3038
摘要： Composition and methods are disclosed for utilizing micro-aggregation of FAP- containing complexes to promote their fast internalization. This approach allows the uptake of cytotoxic cargo coupled to either FAP-Antibodies or FAP-liposome complexes by tumor bladder cells. Importantly, this approach is efficient even under serum- free conditions such as the ones found in the lumen of the bladder.
摘要翻译：公开了组合物和方法，以利用含FAP的络合物的微聚集来促进其快速内化。这种方法允许通过肿瘤膀胱细胞摄取与FAP-抗体或FAP-脂质体复合物偶联的细胞毒性物质。重要的是，即使在无血清条件下，这种方法也是有效的，例如在膀胱内腔中发现的那些。

9. 发明申请

WO2012122544A3 PROTEIN NANOPARTICLE DISPERSIONS 审中-公开
标题翻译：蛋白质纳米颗粒分散体
公开(公告)号：WO2012122544A3
公开(公告)日：2012-11-15
申请号：PCT/US2012028640
申请日：2012-03-09
申请人： UNIV TEXAS , JOHNSTON KEITH P , MAYNARD JENNIFER A , MILLER ANDREA , WILSON BRIAN , TRUSKETT THOMAS M , DININ AILEEN , BORWANKAR AMEYA
发明人： JOHNSTON KEITH P , MAYNARD JENNIFER A , MILLER ANDREA , WILSON BRIAN , TRUSKETT THOMAS M , DININ AILEEN , BORWANKAR AMEYA
IPC分类号： A61K9/12 , A61K9/10 , A61K9/14 , A61K9/16 , A61K47/48
CPC分类号： C07K16/00 , A61K9/0019 , A61K9/19 , A61K47/10 , A61K47/16 , A61K47/183 , A61K47/26 , A61K47/6881
摘要： Provided herein, inter alia, are protein dispersions comprising dense protein nanoclusters and methods of making the. Upon dilution, the clusters may reversibly dissociate into native protein molecules with high biological activity. The viscosities of the nanocluster dispersions may be sufficiently low to allow small-volume subcutaneous injections.
摘要翻译：本文尤其提供了包含致密蛋白质纳米团簇的蛋白质分散体及其制备方法。稀释后，簇可以可逆地解离成具有高生物活性的天然蛋白质分子。纳米簇分散体的粘度可以足够低以允许小体积的皮下注射。

10. 发明申请

WO03103723A2 NEUTROPHIL IMAGING METHODS IN CYCTIC FIBROSIS 审中-公开
标题翻译：中性粒细胞成像方法在CYCTIC FIBROSIS
公开(公告)号：WO03103723A2
公开(公告)日：2003-12-18
申请号：PCT/GB0302392
申请日：2003-06-02
申请人： IMMUNOMEDICS INC , MCCALL JOHN DOUGLAS , GOLDENBERG DAVID M
发明人： GOLDENBERG DAVID M
IPC分类号： G01T1/161 , A61B5/055 , A61B8/00 , A61K47/48 , A61K49/00 , A61K49/04 , A61K49/16 , A61K49/22 , A61K51/00 , A61K51/04 , A61K51/10
CPC分类号： A61K49/0058 , A61K47/6879 , A61K47/6881 , A61K49/0013 , A61K49/0021 , A61K49/0041 , A61K49/0043 , A61K49/006 , A61K49/0404 , A61K49/0433 , A61K49/16 , A61K49/227 , A61K51/0497 , A61K51/1027 , A61K51/1093
摘要： The present invention is directed to an improved method to detect and monitor a subject having cystic fibrosis (CF) by employing at least one anti-granulocyte/neutrophil antibody or a fragment thereof and a diagnostic agent via various imaging methods, wherein said anti-granulocyte antibody is not a murine MN-3 antibody Fab' fragment that is radiolabeled with Tc. Pretargeting methods for improved imaging of granulocytes accumulated in CF are also described. It is further directed to a simple, noninvasive, and effective test that can assess neutrophil delivery to the lower airways of patients with CF and effective test that can assess neutrophil delivery to the lower airways of patients with other neutrophil-mediated lung diseases.
摘要翻译：本发明涉及通过各种成像方法使用至少一种抗粒细胞/嗜中性粒细胞/中性粒细胞抗体或其片段和诊断剂来检测和监测具有囊性纤维化（CF）的受试者的改进方法，其中所述抗粒细胞抗体不是用99M Tc放射性标记的鼠MN-3抗体Fab'片段。还描述了用于改进在CF中累积的粒细胞成像的预靶向方法。它进一步涉及一种简单，无创和有效的测试，可以评估中性粒细胞向CF患者的下呼吸道输送和有效测试，可以评估嗜中性粒细胞向其他嗜中性粒细胞介导的肺部疾病患者的下呼吸道传递。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式